A modification protected one cleavage route but did not solve overall degradation in a published peptide series.
What the study actually tested
Investigators incubated a biotinylated M2 macrophage-targeting peptide in mouse serum and analyzed the remaining material by MALDI-TOF MS. The original M2pepBiotin signal was no longer detected after four hours. N-terminal acetylation protected against N-terminal exopeptidase cleavage, but the acetylated analog still underwent internal cleavage. A D-tryptophan substitution at W10 protected one internal site yet eliminated the binding activity observed for that analog in the study.
Numbers worth reading in context
| Study measure | Reported result |
|---|---|
| Original peptide | not detected at 4 h |
| Protected site | W10/W11 |
| Alternate substitution | D-Trp at W10 |
“Acetylated” is a structural descriptor, not a guarantee of serum stability. The paper separated chemical identity, degradation routes, and target binding: improving one measure changed another. The four-hour observation was an assay result in mouse serum, not a human half-life or a specification for every peptide bearing N-terminal acetylation.
What to put in the RFQ or experiment plan
When ordering an analog for a functional assay, specify the exact N- and C-terminal groups, each D/L residue, label or spacer, and the assay endpoint that matters. If a supplier suggests a stability modification, ask for analytical confirmation of the new structure and test both degradation and function under the intended conditions. Do not treat a same-mass or similar-name analog as interchangeable.
Evidence boundary
This is external preclinical work on a particular peptide family. It is not an NHD batch test, a clinical claim, or evidence that the same modification works for another target.
Sources and next step
Primary research: Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide. These external figures are not test results for an NHD lot.
Related NHD guide: read the related article. For a material-specific question, request a written quotation with the sequence, amount, intended use, and required records.
Sources & editorial method
AI-assisted writing and source verification. Numerical claims were checked against the linked full-text records, with source inconsistencies identified in the article. This is not independent scientific peer review or verification of a supplied lot.
1 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
This is external preclinical work on a particular peptide family. It is not an NHD batch test, a clinical claim, or evidence that the same modification works for another target.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
